文献速递认知障碍与痴呆

血液生物标志物检测阿尔茨海默病临床综合征与非阿尔茨海默病临床综合征中的阿尔茨海默神经病理

Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers.
PubMed 文献 · JAMA Neurol · 2025-02-10

这项尸检临床病理研究纳入349例,评估血浆p-tau217、NfL和GFAP在AD相关综合征与FTLD相关综合征中检测AD神经病理的价值。血浆p-tau217检测AD神经病理的AUC为0.95,在AD相关综合征中AUC为0.98,在FTLD相关综合征中AUC为0.89;NfL和GFAP检测性能较低。FTLD相关综合征中合并AD与更差的认知评分相关。

要点

  • 血浆p-tau217检测AD神经病理总体AUC为0.95。
  • AD相关综合征AUC为0.98,FTLD相关综合征AUC为0.89。
  • FTLD相关综合征合并AD与更差MMSE和认知复合评分相关。

核心结论

  • 临床相关AD在神经退行性综合征中普遍存在,并可通过血浆p-tau217检测。
  • 血浆p-tau217可能是研究非AD神经退行性综合征中AD共病理临床影响的工具,包括疾病修饰治疗的效果。

研究设计与样本

  • 这项临床病理研究于2008年8月至2022年7月在加州大学旧金山分校阿尔茨海默病研究中心进行。
  • 纳入经尸检和神经病理检查、评估时诊断为AD相关临床综合征(n=125)、FTLD(n=198)或认知未受损(CU;n=16)的个体。
  • 使用单分子阵列(SIMOA)测量血浆p-tau217、NfL和GFAP。
  • AD定义为尸检时Intermediate或High AD神经病理改变(ADNC)。
  • 临床生物标志物关联使用线性回归评估,影像分析使用贝叶斯线性混合效应模型。

主要发现

  • 共纳入349例个体(191例[55%]男性;死亡时平均[SD]年龄72[11]岁)。
  • AD在AD相关综合征中常见(110/125[88%]),在FTLD相关综合征中亦常见(45/198[23%])。
  • 尸检神经病理分期在AD相关综合征中更高(High ADNC:AD 82/88[93%] vs FTLD 13/23[56%])。
  • AD在FTLD相关综合征中常被认为是共病理(30/198[15%])。
  • 血浆p-tau217浓度在AD相关综合征(均值[SD] 0.28[0.16] pg/mL)高于FTLD相关综合征(均值[SD] 0.10[0.09] pg/mL)(P < .05)。

关键数值与推荐

  • AD定义为尸检时Intermediate或High ADNC。
  • 血浆p-tau217检测AD神经病理的AUC为0.95(95%CI 0.93-0.97)。
  • AD相关综合征中AUC为0.98(95%CI 0.95-1.00),FTLD相关综合征中AUC为0.89(95%CI 0.83-0.94)。
  • NfL检测AD的AUC为0.73(95%CI 0.68-0.78),GFAP为0.75(95%CI 0.67-0.80)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Blood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD). OBJECTIVE: To investigate the clinical importance and detectability of AD in FTLD-related neurodegenerative syndromes using 3 plasma biomarkers, phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). DESIGN, SETTING, AND PARTICIPANTS: This clinicopathological study took place at the University of California San Francisco Alzheimer Disease Research Center from August 2008 to July 2022. Autopsied individuals with clinical evaluation and neuropathological examination, diagnosed with clinical syndromes related to AD (n = 125), frontotemporal lobar degeneration (FTLD; n = 198), or cognitively unimpaired (CU) at the time of evaluation (n = 16) were included. EXPOSURES: AD-related or FTLD-related clinical syndromes or CU. MAIN OUTCOMES AND MEASURES: P-tau217, NfL, and GFAP were measured with single-molecule array (SIMOA). AD was defined as intermediate or high AD neuropathological change (ADNC) at autopsy. Clinical biomarker associations were evaluated using linear regressions. Imaging analyses used bayesian linear mixed-effects modeling. RESULTS: A total of 349 individuals (191 [55%] male; mean [SD] age at death, 72 [11] years) were included. AD was common in both AD-related syndromes (110/125 [88%]) and FTLD-related syndromes (45/198 [23%]). Neuropathological stage at autopsy was higher in AD-related syndromes (high ADNC: 82/88 [93%] AD vs 13/23 [56%] FTLD), and AD was frequently considered a copathology in FTLD-related syndromes (30/198 [15%]). Plasma p-tau217 concentrations were higher in AD-related syndromes (mean [SD], 0.28 [0.16] pg/mL) than FTLD-related syndromes (mean [SD], 0.10 [0.09] pg/mL) (P < .05). Plasma p-tau217 concentrations were highest in atypical AD-related syndromes (mean [SD], 0.33 [0.02] pg/mL), followed by typical late-onset amnestic syndromes (mean [SD], 0.27 [0.03] pg/mL). FTLD-related syndromes with AD (mean [SD], 0.19 [0.02] pg/mL) were higher compared to without (mean [SD], 0.07 [0.00] pg/mL). Plasma p-tau217 detected AD neuropathology across syndromes (area under the receiver operating characteristic curve [AUC], 0.95; 95% CI, 0.93-0.97), with slightly better performance in AD-related syndromes (AUC, 0.98; 95% CI, 0.95-1.00) compared to FTLD-related syndromes (AUC, 0.89; 95% CI, 0.83-0.94). NfL and GFAP had lower performance for detecting AD (AUC, 0.73; 95% CI, 0.68-0.78 and AUC, 0.75; 95% CI, 0.67-0.80, respectively) and added little to no diagnostic value either alone or in combinations with p-tau217. The presence of AD in FTLD-related syndromes was associated with lower Mini-Mental State Examination score (mean [SD], -2.90 [1.09]; P < .05), worse performance on memory (mean [SD] z score, -0.64 [0.32]), executive (mean [SD] z score, -0.74 [0.19]), and visuospatial composites (mean [SD] z score, -0.88 [0.37]) as well as increased rates of posterior cortical atrophy. CONCLUSION: Clinically relevant AD was prevalent across neurodegenerative syndromes and detectable with plasma p-tau217. Plasma p-tau217 may be a useful tool to investigate the clinical impact of AD copathology in non-AD neurodegenerative syndromes, including the effect of disease-modifying therapies.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. VandeVrede L, Cho H, Sanderson-Cimino M, et al. Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers. JAMA Neurol. 2025. PMID: 39928343. doi:10.1001/jamaneurol.2024.5017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。